TY - JOUR
T1 - Tumor‐associated antigens in breast carcinomas. Prognostic significance
AU - Cohen, Cynthia
AU - Sharkey, Francis E.
AU - Shulman, Gerald
AU - Uthman, Edward O.
AU - Budgeon, Lynn R.
PY - 1987/9/15
Y1 - 1987/9/15
N2 - In an attempt to identify biologic markers that might predict prognosis in breast cancer patients, the presence or absence of seven tumor‐associated antigens in 54 infiltrating breast carcinomas was correlated with tumor recurrence rates (minimum five‐year follow‐up), axillary lymph node metastases and tumor volume. Immunohistochemical kappa‐casein was present in 30 (56%) tumors, alpha‐lactalbumin in 39 (72%) tumors, secretory component of IgA in 26 (48%) tumors, carcinoembryonic antigen in 34 (63%) tumors, pregnancy‐specific beta‐1‐glycoprotein in 7 (13%) tumors, beta subunit of human chorionic gonadotrophin in 1 (2%) tumor and human placental lactogen in 0 (0%) tumors. There was no significant correlation between the presence or absence in tumor of any of the antigens, and prognosis as assessed either by 5‐year recurrence rates (P > 0.18) or by the presence of axillary lymph node metastases (P > 0.20). No significant difference was noted in mean tumor volume (cm3) ±SEM, between tumors with or without antigen immunoreactivity (P > 0.05).
AB - In an attempt to identify biologic markers that might predict prognosis in breast cancer patients, the presence or absence of seven tumor‐associated antigens in 54 infiltrating breast carcinomas was correlated with tumor recurrence rates (minimum five‐year follow‐up), axillary lymph node metastases and tumor volume. Immunohistochemical kappa‐casein was present in 30 (56%) tumors, alpha‐lactalbumin in 39 (72%) tumors, secretory component of IgA in 26 (48%) tumors, carcinoembryonic antigen in 34 (63%) tumors, pregnancy‐specific beta‐1‐glycoprotein in 7 (13%) tumors, beta subunit of human chorionic gonadotrophin in 1 (2%) tumor and human placental lactogen in 0 (0%) tumors. There was no significant correlation between the presence or absence in tumor of any of the antigens, and prognosis as assessed either by 5‐year recurrence rates (P > 0.18) or by the presence of axillary lymph node metastases (P > 0.20). No significant difference was noted in mean tumor volume (cm3) ±SEM, between tumors with or without antigen immunoreactivity (P > 0.05).
UR - http://www.scopus.com/inward/record.url?scp=0023617113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023617113&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19870915)60:6<1294::AID-CNCR2820600622>3.0.CO;2-2
DO - 10.1002/1097-0142(19870915)60:6<1294::AID-CNCR2820600622>3.0.CO;2-2
M3 - Article
C2 - 3040212
AN - SCOPUS:0023617113
SN - 0008-543X
VL - 60
SP - 1294
EP - 1298
JO - Cancer
JF - Cancer
IS - 6
ER -